MOLOGEN AG
MOLOGEN AG: 2013 annual financial statements submitted – pivotal study for MGN1703 under preparation
MOLOGEN AG / Key word(s): Final Results MOLOGEN AG: 2013 annual financial statements submitted – pivotal study for MGN1703 under preparation – For the first time three product candidates in clinical development phase – Final evaluations of the clinical trials provide positive data – Cash consumption at level of previous year despite increased research activity – Clinical phase III study for cancer immunotherapy MGN1703 is being prepared Berlin, March 25, 2014 – MOLOGEN AG completed a successful financial year 2013 with three different product candidates in clinical development for the first time. The final evaluations for the completed clinical trials of MGN1703 and MGN1601 provided very positive data, and with MGN1404 (a product that combats malignant melanoma) the clinical development phase of another product candidate was launched within the framework of a cooperation and is therefore contributing to an expansion of the pipeline. The company closed the financial year 2013 with a net loss of 10.8 million euros, 7.9 million euros of which accounted for research and development costs. On the reporting date as of December 31, 2013, MOLOGEN AG had liquid funds in the total amount of 14.8 million euros. An additional 15.7 million euros could be raised with the capital increase carried out in February 2014. MOLOGEN’s financial position is therefore solid in terms of the planned research projects. Research results confirm the potential of products – pivotal study being prepared MOLOGEN was able to confirm the preliminary data collected from the phase I/II trials with MGN1601 in the indication of renal cancer (ASET study). The results showed a good safety and tolerability for this therapeutic cancer vaccine, meaning that the primary study endpoint was achieved. In addition, the promising data in terms of the overall survival of patients in a subgroup exceeded the expectations. With MOLOGEN’s most advanced product candidate, the cancer immunotherapy MGN1703, very positive clinical data from the final evaluation of a phase II trial in the indication of colorectal cancer (IMPACT study) was also able to be presented in 2013. In addition to the convincing results for progression-free survival immunological biomarkers were also analyzed. This resulted in valuable scientific findings with regard to the further development of MGN1703, for example, on the question of which patients could benefit from a treatment. Overall, the final evaluation provided evidence of the efficacy of MGN1703 together with an exceptionally good tolerability. The preparations for a phase III pivotal study in this indication were completed for the most part in the course of the last financial year. At the same time, an application was made in 2013 for a phase II trial using the same product in the indication of small cell lung cancer (IMPULSE study), another cancer with a high demand for medical treatment. That could extend the scope of application of MGN1703 in addition to colorectal cancer. Towards the end of the financial year a safety study with MGN1703 was also conducted in the United States, and its treatment phase was concluded. The study forms the basis for also being able to promote the further clinical development of MGN1703 in parallel in the United States. Finances With 14.8 million euros as of December 31, 2013, the liquid funds at MOLOGEN AG were lower than those of the previous year (2012: 23.8 million euros). In February 2014 the company was also able to receive gross proceeds of 15.7 million euros through a capital increase. Outlook In addition, MOLOGEN is planning the launch of the IMPULSE study for 2014, a randomized and controlled study with MGN1703 in small cell lung cancer. Planning and preparation of an advanced clinical trial for MGN1601 is also scheduled. As a result of these research activities, MOLOGEN assumes that there will be a significant increase in the costs of research and development and the associated outflow of liquid funds in financial year 2014. Overall, the Executive Board expects another negative annual result. A possible out-licensing of the drug candidate MGN1703 is not taken into consideration in this scenario and could have significant positive effects on results and on the liquidity situation. Dr. Matthias Schroff, chairman of the Executive Board of MOLOGEN AG says, “Due to the results we presented relating to the study of our cancer immunotherapy MGN1703 in the application against colorectal cancer, which were also well-received in professional circles, we have great faith in the pivotal study for this product candidate. MOLOGEN is therefore one of the few biotech companies in Germany which is able to bring a product into a phase III study completely independently. In addition, the MOLOGEN pipeline contains other drug candidates, particularly in the field of cancer immunotherapies, which all have a large market potential. Against this background, we are very confident with regard to the current financial year 2014.” The complete 2013 annual report of MOLOGEN AG is available for download from the company’s website: www.mologen.com/en/investor-relations/publications/financial-reports.html About MOLOGEN AG With unique, patented technologies and innovative product developments, MOLOGEN is one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies. MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
PRESS SERVICE: INVESTOR RELATIONS: External Investor Relations: Note about risk for future predictions
End of Corporate News 25.03.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
259314 25.03.2014 |